Sublingual immunotherapy and subcutaneous immunotherapy: Issues in the United States

Paul A. Greenberger*, Mark Ballow, Thomas B. Casale, Thomas A.E. Platts-Mills, Hugh A. Sampson

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)1466-1468
Number of pages3
JournalJournal of Allergy and Clinical Immunology
Volume120
Issue number6
DOIs
StatePublished - Dec 2007

Funding

Disclosure of potential conflict of interest: P. A. Greenberger has consulting arrangements with Novartis and has received grant support from the National Heart, Lung, and Blood Institute. M. Ballow has consulting arrangements with Talecris Therapeutics and is on the speakers' bureau for Merck and AstraZeneca. T. B. Casale has consulting arrangements with Dynavax and has received grant support from Dynavax, Curalogic, and Allergy Therapeutics. T. A. E. Platts-Mills has consulting arrangements with Indoor Biotechnologies and has received grant support from the National Institute of Allergy and Infectious Diseases. H. A. Sampson has consulting arrangements with Allertein.

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this